4CPS-035 Effectiveness and safety of monoclonal antibody pcsk9 inhibitors

BACKGROUND: Monoclonal antibody PCSK9-Inhibitors (PCSK9i), alirocumab and evolocumab, are a new class of drugs used to decrease LDL cholesterol (LDLc) and can be an option for patients with heterozygous familial hypercholesterolaemia (HeFH) and cardiovascular diseases (CVD) with high levels of LDLc...

詳細記述

保存先:
書誌詳細
出版年:Eur J Hosp Pharm
主要な著者: Martin, V Merino, Ortega-Garcia, MP, Blasco-Segura, P, Garcia, J Sanfeliu, Carrasco, A Lopez, Cristobal, R del Rio San, Guasp, I Toledo
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Group 2018
主題:
Section 4: Clinical pharmacy services
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535419/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.126
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料